Scholarlink

Aim <p>To evaluate clinical outcomes, treatment intervals, and safety outcomes of brolucizumab (BRO) treatment in a national neovascular age-related macular degeneration (nAMD) database.</p> Methods <p>Multicentre, national, routine clinical care database study of nAMD eyes receiving ≥1 BRO injection. Demographics, visual acuity (VA) measured in logMAR letters, macular neovascularization (MNV) activity, number of injections, visit data and information on any adverse events were collected at baseline and at 3, 6, 9 and 12 months after BRO initiation for each patient/eye.</p> Results <p>A total of 305 eyes received <InlineEquation ID="IEq1"> <InlineMediaObject> <ImageObject Color="BlackWhite" FileRef="41433_2025_3871_Article_IEq1.gif" Format="GIF" Height="15" Rendition="HTML" Resolution="72" Type="Linedraw" Width="19" /> </InlineMediaObject> <EquationSource Format="TEX">\(\ge \)</EquationSource> <EquationSource Format="MATHML"><math> <mo>≥</mo> </math></EquationSource> </InlineEquation>1 BRO injection and 214 eyes (14% naïve, 86% switchers) completed <InlineEquation ID="IEq2"> <InlineMediaObject> <ImageObject Color="BlackWhite" FileRef="41433_2025_3871_Article_IEq1.gif" Format="GIF" Height="15" Rendition="HTML" Resolution="72" Type="Linedraw" Width="19" /> </InlineMediaObject> <EquationSource Format="TEX">\(\ge \)</EquationSource> <EquationSource Format="MATHML"><math> <mo>≥</mo> </math></EquationSource> </InlineEquation>3 months follow-up. In switchers, the percentage of eyes extended to ≥8 week intervals at 3/6/9 months was 43.2%/45.7%/54.5% and to ≥10 week intervals was 12.9%/18.5%/13.6%, respectively. Eyes with VA ≥ 70 increased from 36% at baseline to 48% at 3 months and 50% at 9 months. MNV lesion activity status decreased from 94% (active/active-only SRF, 46/48%) at baseline to 56% (21/35%), 61% (23/38%), 76% (27/49%) and 65% (24/41%) at months 3/6/9 and 12, respectively. Adverse effects were observed in 6.5% of the treated eyes, being the most prevalent anterior uveitis (3.2%), vitritis (4.5%) and vasculitis (2.2%).</p> Conclusion <p>In this series BRO achieves an extension in the treatment intervals in half of the patients which require frequent reinjections (&lt;8 weekly), reducing MNV activity in a third of this specific difficult-to-treat subgroup. The adverse event rates described are consistent with other cohorts and need to be considered to inform treatment decisions in case-by-case discussions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brolucizumab clinical and safety outcomes in a neovascular age-related macular degeneration national database: Fight Retinal Blindness Spain (FRB Spain)

  • 期刊论文

  • 发表日期：

    2025年6月5日

查看全文
  • Javier Zarranz-Ventura,
  • Sonia Marías-Pérez,
  • Ruben Martin-Pinardel,
  • Manel Fernandez-Bonet,
  • Begoña Pina-Marin,
  • Estefanía Cobos,
  • Carmen Antía Rodríguez-Fernandez,
  • Alba Parrado-Carrillo,
  • Isaac Alarcón-Valero,
  • Carles Barnes,
  • Esther Cilveti,
  • Julia Aramburu-Claveria,
  • Francisco J. Ascaso-Puyuelo,
  • Pilar Calvo,
  • Maria Pilar Ruiz-del-Tiempo,
  • Gabriela Susanna-González,
  • Marc Figueras-Roca,
  • Ricardo P. Casaroli-Marano,
  • Carolina Bernal-Morales,
  • Javier Zarranz-Ventura,
  • Alba Parrado-Carrillo,
  • Marc Figueras-Roca,
  • Aina Moll-Udina,
  • Jordi Izquierdo-Serra,
  • Carolina Bernal-Morales,
  • Alba Serrano,
  • Sofia Batllé-Ferrando,
  • Jose Grau,
  • Socorro Alforja,
  • Ricardo P. Casaroli-Marano,
  • Laura Sararols-Ramsay,
  • Gabriel Londoño,
  • Maximiliano Olivera,
  • Karim Bañon,
  • Cynthia Rethati,
  • Pilar Calvo,
  • Jorge Sánchez,
  • Martín Puzo,
  • Maria Pilar Ruiz-Del-Tiempo,
  • Oscar Ruiz-Moreno,
  • Gonzaga Garay-Aramburu,
  • Arantza Larrauri-Arana,
  • Angela Gómez-Moreno,
  • David Rodríguez-Feijoo,
  • Enrique Diaz-de-Durana-Santa-Coloma,
  • Maialen Aldazabal-Echeveste,
  • Zuriñe del-Barrio-Lopez-de-Ipiña,
  • Irene Herrero-Díaz,
  • Miguel Angel Zapata,
  • Helena Brosa,
  • José García-Arumí,
  • Laura Sánchez-Vela,
  • Carolina Arruabarrena,
  • Rafael Montejano-Milner,
  • Fernando de Aragón,
  • Maximino José Abraldes López-Veiga,
  • María Lidia Gómez-Conde,
  • María José Rodríguez-Cid,
  • María Isabel Fernández-Rodríguez,
  • Pablo Almuiña-Varela,
  • Ana Fernández-Hortelano,
  • Jesús Zarallo-Gallardo,
  • Rosario Cobo-Soriano,
  • Inmaculada Lozano-Escobar,
  • Paula Moreno-Martín,
  • Jose Maria Ruiz-Moreno,
  • Rocío Vega-González,
  • María García-Zamora,
  • Ignacio Flores-Moreno,
  • Xavier Valldeperas,
  • Laura Broc-Iturralde,
  • Ferran Vilaplana-Mira,
  • Sandra Gómez Sánchez,
  • Pamela Campos Figueroa,
  • Jose Juan Escobar-Barranco,
  • Begoña Pina-Marín,
  • Eva Salinas Martínez,
  • Jacobo González Guijarro,
  • Muxima Acebes García,
  • Sonia Aparicio Sanchís,
  • Jonathan Cacelliere Fernández,
  • Marta Belmonte Grau,
  • Francisco Javier Ascaso-Puyuelo,
  • Ana Honrubia Grijalbo,
  • Ana Boned Murillo,
  • Julia Aramburu,
  • María Dolores Díaz Barreda,
  • Roberto Gallego-Pinazo,
  • Marta Cholbi,
  • Rosa Dolz-Marco,
  • Marta S. Figueroa,
  • Esther Ciancas,
  • Julio José Gonzalez-López,
  • Cesar Azrak Haskour,
  • Alvaro Piñero Sánchez,
  • Nélida Muñoz Sanz,
  • Ester Carreño,
  • Nestor Ventura,
  • Pablo Carnota-Méndez,
  • Carlos Méndez-Vázquez,
  • Carlos Torres-Borrego,
  • Daniel Velázquez-Villoria,
  • Alfredo García-Layana,
  • Manuel Saenz de Viteri,
  • Elena Alonso,
  • Patricia Fernandez-Robredo,
  • Sergio Recalde,
  • Ainara Chas,
  • Maria Hernandez-Sanchez,
  • Sara Llorente,
  • Angel Salinas-Alamán,
  • Jaione Bezunartea,
  • Luis J. Castillón Torre,
  • Pablo Catalán Muñoz,
  • María Eugenia Tena Sempere,
  • María de Fátima Álvarez Gil,
  • Purificación Piñas García,
  • María Eugenia Mantrana Bermejo,
  • Francisco Javier Lavid de los Mozos,
  • Mónica Asencio Duran,
  • Lluis Arias-Barquet,
  • Estefanía Cobos,
  • Daniel Lorenzo,
  • Carmen A. Rodríguez-Fernández,
  • Marta Rodríguez-Núñez,
  • Ana Campo Gesto,
  • Jesús Pareja Esteban,
  • Mariano Rodríguez-Maqueda,
  • María Angeles Espiñeira Periñan,
  • Magdalena Sotomayor Toribio,
  • Isaac Alarcon-Valero,
  • Carles Barnes,
  • Esther Cilveti,
  • Stefani Carrillo,
  • Lucia Miguel-Escuder

摘要

Aim

To evaluate clinical outcomes, treatment intervals, and safety outcomes of brolucizumab (BRO) treatment in a national neovascular age-related macular degeneration (nAMD) database.

Methods

Multicentre, national, routine clinical care database study of nAMD eyes receiving ≥1 BRO injection. Demographics, visual acuity (VA) measured in logMAR letters, macular neovascularization (MNV) activity, number of injections, visit data and information on any adverse events were collected at baseline and at 3, 6, 9 and 12 months after BRO initiation for each patient/eye.

Results

A total of 305 eyes received \(\ge \) ≥ 1 BRO injection and 214 eyes (14% naïve, 86% switchers) completed \(\ge \) ≥ 3 months follow-up. In switchers, the percentage of eyes extended to ≥8 week intervals at 3/6/9 months was 43.2%/45.7%/54.5% and to ≥10 week intervals was 12.9%/18.5%/13.6%, respectively. Eyes with VA ≥ 70 increased from 36% at baseline to 48% at 3 months and 50% at 9 months. MNV lesion activity status decreased from 94% (active/active-only SRF, 46/48%) at baseline to 56% (21/35%), 61% (23/38%), 76% (27/49%) and 65% (24/41%) at months 3/6/9 and 12, respectively. Adverse effects were observed in 6.5% of the treated eyes, being the most prevalent anterior uveitis (3.2%), vitritis (4.5%) and vasculitis (2.2%).

Conclusion

In this series BRO achieves an extension in the treatment intervals in half of the patients which require frequent reinjections (<8 weekly), reducing MNV activity in a third of this specific difficult-to-treat subgroup. The adverse event rates described are consistent with other cohorts and need to be considered to inform treatment decisions in case-by-case discussions.